Table 1.

Assessment of in vitro curcumin sensitivity in leukemic cells from B-CLL patients

Patient no.Rai stageWBC/ALC (×109/L)CD38*ZAP-70IGH statusFISHCurcumin IC50 (μmol/L) range
1IV163.9/144.15NegativeNegativeUM13q-12.5
2IV30/16.91PositiveNDUMND10.0
3I25.5/14.53NegativeNegativeND11q-10-12.5
4I55.4/51.69NegativeNegativeM13q-10-12.5
5I32.5/26.32PositivePositiveUM13q-12.5-15.0
6IV79.1/66.44NegativePositiveND17p-15.0
7II100.8/97.77NegativePositiveUM11q-15-20
8I61.4/58.33NegativeNegativeMNormal12.5-15.0
9II45.9/44.06PositivePositiveUMTrisomy 1210-12.5
10I29.8/27.11NDPositiveUM13q-12.5
11IV56.2/50.58NegativeNegativeNDTrisomy 1210-12.5
12I40.5/38.47PositivePositiveUM6q-10-12.5
13I42.8/33.81NegativeNegativeM13q-12.5-15.0
14II23.9/12.66PositiveNegativeNDTrisomy 1210-12.5
15I43.1/32.32PositiveNDUMTrisomy 125-7.5
16046.2/42.04NDPositiveUMNormal10-12.5
17III19.4/17.04PositivePositiveUM13q-7.5-10.0
18I31.1/26.74NegativeNegativeNDNormal7.5-10.0
  • Abbreviations: ALC, absolute lymphocyte count; ZAP-70, Zeta-associated protein 70; IGH, Immunoglobin heavy chain mutation status; UM, unmutated; M, mutated; ND, not done; FISH, fluorescence in situ hybridization.

  • * Cutoff value, ≥30%.

  • Cutoff value, ≥20%.